Fluicell AB

FLUI · Nasdaq Stockholm · Healthcare

30.00SEK +2.4%last day

Price as of 2 October 2026

The price over the past year, with dividends: +48.5%

Performance

1 month

−4.2%

1 year

+48.5%

3 years, per year

−29.9%

5 years, per year

−58.0%

Largest fall, 3 years

−99.5%

Below the peak now

−99.0%

Volatility, 1 year

114.3%

Return with dividends reinvested.

Key figures

P/E

14.2

P/B

2.4

Dividend yield

0.0%

Return on equity

+17.0%

Net margin

+14.1%

Market value

4 m USD

Quality, value and trend

Where Fluicell stands against every Nordic stock today. 100 is best.

Quality97

Profitability and a sound balance sheet over time. Better than 97% of Nordic stocks.

Value56

The price measured against earnings, assets and cash flow. Better than 56% of Nordic stocks.

Trend74

The price development over the past year. Better than 74% of Nordic stocks.

Combined93

Quality, value and trend together. Better than 93% of Nordic stocks.

About Fluicell

Fluicell AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 11 employees.

Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis